Dr John Melki – CEO and Director – Genetic Signatures (ASX:GSS) is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.
Copyright 2023 – Finance News Network
Source: Finance News Network
10 Oct 2023 - Jon Price - Managing Director - Richmond Vanadium Technology (ASX:RVT) is an Australian minerals development company which is advancing the Richmond – Julia Creek Vanadium Project in Queensland through a Bankable Feasibility Study.
Read More04 Mar 2024 - Sean Gregory - Managing Director - Sarytogan Graphite (ASX:SGA) through its 100% owned subsiduary company, Ushtogan LLP, is the 100% owner of the Sarytogan Graphite Project. The Sarytogan Graphite Project is located in the Karaganda region of Central Kazakhstan and the exploration concession covers 70 km2. As its name suggests, the Sarytogan Graphite Project is prospective for graphite and a meaningful initial JORC compliance resource has already been delineated on the project.
Read More17 Nov 2022 - Genetic Signatures Limited (ASX:GSS) CEO and Director Dr John Melki discusses the company's technology, business model, 2022 highlights and outlook.
Read More29 07 2024 - Neil McIntyre - CEO - Diatreme Resources (ASX:DRX) is an emerging Australian producer of mineral and silica sands based in Brisbane. Our key projects comprise the Northern Silica Project and Galalar Silica Sand Project in Far North Queensland, located next to the world's biggest silica sand mine at Cape Flattery.
Read More28 Feb 2024 - Chris Stevens - Chief Executive Officer & Executive Director - Coda Minerals (ASX:COD) is an advanced exploration company primed to unlock the value of the highly prospective Elizabeth Creek Copper Cobalt Project in South Australia’s world class mining jurisdiction, the Gawler Craton.
Read More21 Sep 2021 - An introduction to newly appointed BluGlass Limited (ASX:BLG) President, Jim Haden.
Read More10 Mar 2020 - Opthea Limited (ASX:OPT) Managing Director and CEO, Dr Megan Baldwin talks about results from the company's lead drug candidate OPT-302, and new funding for further clinical development for wet AMD (age-related macular degeneration) and DME (diabetic macular degeneration).
Read More07 Sep 2022 - IVE Group (ASX:IGL) Executive Chairman Geoff Selig discusses full-year results, the recent acquisition of Ovato and the launch of the Lasoo e-commerce platform.
Read More26 Feb 2021 - Anteris Technologies Limited (ASX:AVR) CEO & Managing Director Wayne Paterson talks about the benefits of the company's Anteris DurAVR aortic replacement valve to work better and for longer, company strategy and goals for 2021.
Read More06 Jan 2021 - Nyrada Limited (ASX:NYR) CEO James Bonnar discusses the cholesterol-lowering market, and recent results for the company's lead drug candidate, which achieved a 57% reduction in total cholesterol.
Read More
